Layoffs
Filter News
Found 51 articles
-
Novartis is closing its generic-drug manufacturing facility in Broomfield, Colo., which will cut 450 jobs over two years.
-
An investor decision to renege on acquiring more than $3 million worth of stock has created a financial catastrophe for Biostage.
-
PhaseRx has undertaken a strategic restructuring that includes the termination of 50 percent of its staff.
-
As Johnson & Johnson's Animas Shuts Down, Insulet Eyes Its Customers
10/10/2017
-
Bio-Rad to Shut Down Cambridge R&D Site in Consolidation
10/9/2017
-
Xtant Medical to Shutter Dayton Facility, 55 Employees Affected
10/9/2017
-
Johnson & Johnson's Animas to Shut Down Ops and Exit Insulin Pump Biz, 410 Jobs Affected
10/6/2017
-
AstraZeneca PLC May Move Some Manufacturing, R&D Out Of The UK Due To Brexit
10/4/2017
-
Shiel Medical to Pink Slip 538 Employees Ahead of Quest Diagnostics Acquisition
10/3/2017
-
Bay Area's Mateon Therapeutics Cuts 60% of Jobs, Terminates Ovarian Cancer Drug From Pipeline
9/28/2017
-
Stock Plummets as Genocea Axes 40% of Jobs, Shifts R&D Focus in Restructuring
9/27/2017
-
EMA Warns of Major Staff Losses, Delayed Drug Approvals in HQ Relocation
9/27/2017
-
Graphic Controls to Move Vermed Medtech Jobs to Buffalo, Dozens of New Positions Created
9/22/2017
-
Nestle's Galderma Laboratories to Slash Up to 450 Jobs at R&D Center
9/21/2017
-
Boston's Juniper Pharma Suspends Program, Cuts 8% of R&D Jobs and CMO Steps Down
9/20/2017
-
Otonomy Slashes 33% of Staff After Failed Phase III Clinical Trial for Meniere’s Disease
9/14/2017
-
Alexion Wants a Fresh Start, Slashes 20% of Jobs and Will Move HQ to Boston
9/13/2017
-
Lombard Medical Restructures, Implements Strategic Plan to Achieve Profitability
9/13/2017
-
Unknown Number of Employees Impacted as ESSA Pharma Restructures and Refocuses R&D
9/11/2017